BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

979 related articles for article (PubMed ID: 23846820)

  • 21. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
    Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
    Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.
    Fulghesu AM; Romualdi D; Di Florio C; Sanna S; Tagliaferri V; Gambineri A; Tomassoni F; Minerba L; Pasquali R; Lanzone A
    Hum Reprod; 2012 Oct; 27(10):3057-66. PubMed ID: 22786777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
    Alpañés M; Álvarez-Blasco F; Fernández-Durán E; Luque-Ramírez M; Escobar-Morreale HF
    Eur J Endocrinol; 2017 Nov; 177(5):399-408. PubMed ID: 28912358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
    Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
    Petrányi G; Zaoura-Petrányi M
    Orv Hetil; 2011 Apr; 152(16):628-32. PubMed ID: 21454179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
    Mitkov M; Pehlivanov B; Terzieva D
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
    Pau CT; Keefe C; Duran J; Welt CK
    J Clin Endocrinol Metab; 2014 May; 99(5):1870-8. PubMed ID: 24606093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
    Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
    Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
    Palomba S; Falbo A; Russo T; Manguso F; Tolino A; Zullo F; De Feo P; Orio F
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3128-35. PubMed ID: 17519312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
    Le Donne M; Alibrandi A; Giarrusso R; Lo Monaco I; Muraca U
    Minerva Ginecol; 2012 Feb; 64(1):23-9. PubMed ID: 22334228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
    Glintborg D; Altinok ML; Mumm H; Hermann AP; Ravn P; Andersen M
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2584-91. PubMed ID: 24742124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.